Navigation Links
The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting

NEW YORK, Dec. 21 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

Very small embryonic-like stem cells are a population of heterogeneous stem cells found in the bone marrow that have properties similar to those of an embryonic stem cell and provide the promise of achieving the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or certain of the potential negative effects associated with embryonic stem cells. Important aspects of the basic understanding of why very small embryonic-like stem cells appear to be effective in clinical situations were demonstrated by the multiple presentations at the recent ASH meeting given by Dr. Mariusz Ratajczak's team of researchers from the Stem Cell Institute at the James Brown Cancer Center, University of Louisville. These reports, among other things, addressed the epigenetic and genetic mechanisms that control and modify the functions of very small embryonic-like stem cells; the role of growth factors in the regulation of proliferation of very small embryonic-like stem cells; and the maintenance of very small embryonic-like stem cells in a quiescent state from the embryogenesis through adulthood, when they contribute to the steady-state conditions of tissue rejuvenation and to the regeneration of damaged organs during emergencies. It is anticipated that these seminal studies of the fundamental mechanisms by which these stem cells play their pivotal role in tissue regeneration will significantly contribute to the efficiency and efficacy of future clinical applications of very small embryonic-like stem cells.

Clinical reports on very small embryonic-like stem cells published in peer-reviewed journals during 2009 include those addressing:

Retinal diseases: A potential application of very small embryonic-like stem cells for retinal diseases as described by Dr. Anna Machalinska and colleagues from the Pomeranian Medical University, Szczecin, Poland in a paper published in September in the journal Current Eye Research.

Cardiac Disease: The application of very small embryonic-like stem cells for cardiac disease as described by Drs. Dawn Tiwari, Roberto Bolli and others from the Institute of Molecular Cardiology, University of Louisville School of Medicine who published their findings in June in the journal Stem Cells on the ability of very small embryonic-like stem cells to reduce the damage to the heart caused by acute myocardial infarction. In addition, very small embryonic-like stem cells were shown to increase in the circulation of patients who have suffered an acute myocardial infarction as published in the Journal of the American College of Cardiology in January by Dr. Wojciech Wojakowski and colleagues from the Medical College of Silesia, Katowice, Poland. Very small embryonic-like stem cells have been shown to be mobilized by the body in response to disease suggesting that these cells have a central role in cardiac tissue repair.

Cerebral Vascular Disease: The increase in circulating very small embryonic-like stem cells in patients following a stroke was published in the journal Stroke in April by Edyta Paczkowska and her colleagues from the Pomeranian Medical University, Szczecin, Poland. Further evidence of the importance of very small embryonic-like stem cells in aging is provided by a paper from the Stem Cell Institute at the James Brown Cancer Center, University of Louisville authored by the group led by Dr. Mariusz Ratajczak. This paper suggests that these cells may decelerate the aging process through rejuvenation of adult tissue and was published in the journal Mechanisms of Aging and Development, January-February issue. These two papers strongly support a role of very small embryonic-like stem cells in tissue regeneration.

Dr. Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "The medical literature increasingly supports the potential of very small embryonic-like stem cells as therapy in regenerative medicine. NeoStem will continue to support basic cell biology studies elucidating the unique properties of very small embryonic-like stem cells and exploring the therapeutic use of VSEL(TM) technology for the treatment of a wide range of diseases and conditions." Dr. Smith further added, "We believe that access to a continuous source of stem cells through our stem cell collection and banking program will allow us to implement our own regenerative medicine applications on an ongoing basis that could eventually result in a fundamental shift in the way healthcare is administered."

About NeoStem, Inc.

NeoStem is engaged in the business of developing stem cell-based therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. For more information, please visit:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the potential use of very small embryonic-like for the treatment of disease and for regenerative purposes, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on December 15, 2009 as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    NeoStem, Inc.
    Robin Smith, Chief Executive Officer
    T: 212-584-4180

SOURCE NeoStem, Inc.

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BSGI Makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings
2. Reportlinker Adds Injectable Drug Delivery: Market Impact and Industry Trends
3. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
4. Reportlinker Adds Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, initiatives and insights for supply chain integrity
5. Growing Supply Chain Complexity Increasing Impact on Medical Device Company Operations
6. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
7. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
8. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
9. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccines Impact on Cervical Cancer Prevention
10. SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts
11. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):